- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03634020
DynamX Sirolimus Study Sirolimus Eluting Coronary Bioadaptor System
Evaluation of a Thin Strut Metallic Coronary Device: the Elixir DynamXTM Sirolimus Eluting Coronary Bioadaptor System
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The DynamX Sirolimus Study is a prospective, consecutive enrollment, single-arm study designed to enroll up to 30 patients requiring treatment of up to two de novo lesions ≤ 24 mm in length in vessels ≥ 2.5 mm and ≤ 3.5 mm in diameter.
One or two designated target lesions, located in separate epicardial vessels (RCA, LCX or LAD), and meeting the inclusion/exclusion criteria may be treated with the DynamX SECBS. Alternatively, one target lesion may be treated with the DynamX SECBS after successful, uncomplicated treatment of a non-target lesion, located in a separate epicardial vessel, with any commercially-available DES. Acceptable example: non-target RCA lesion and LAD target lesion. Not acceptable example: LAD non-target lesion and 1st diagonal target lesion.
The primary safety endpoint is Target Lesion Failure at 6 months. TLF is a composite endpoint defined as cardiac death, target vessel MI, and clinically-indicated target lesion revascularization The primary efficacy endpoint is late lumen loss at 6 months, assessed by angiography Additional secondary safety and effectiveness endpoints will be evaluated at 30 days, 6 and 12 months Using visual assessment, the target lesion must measure ≥ 2.5 mm and ≤ 3.5 mm in diameter and ≤ 24 mm in length able to be covered by a single DynamX Sirolimus Bioadaptor including 2 mm of healthy vessel on either side of the planned treatment area.
The patient will be eligible for stent (also called bioadaptor) implantation only after satisfactory lesion pre-dilatation defined as: ≥ TIMI 2 flow, and no dissection greater than Grade B (NHLBI) able to be covered with a single DynamX SECBS
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Auckland, New Zealand
- Middlemore Hospital
-
Auckland, New Zealand, 1023
- Auckland City Hospital
-
Auckland, New Zealand, 0622
- North Shore Hospital
-
Christchurch, New Zealand
- Christchurch Hospital
-
Dunedin, New Zealand
- Dunedin Hospital
-
Hamilton, New Zealand
- Waikato Hospital
-
Wellington, New Zealand, 6023
- Wellington Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient must be at least 18 years of age
- Patient is able to understand the risks, benefits and treatment alternatives of receiving the DynamX Sirolimus Eluting CBS and provide written informed consent, as approved by the NZ Ethics Committee, prior to any clinical study-related procedure
- Patient must have evidence of myocardial ischemia (e.g., stable or unstable angina, silent ischemia, positive functional study or electrocardiogram (ECG) changes consistent with ischemia)
- Patient must be an acceptable candidate for coronary artery bypass graft (CABG) surgery
- Women of childbearing potential with a negative pregnancy test within 7 days and women who are not pregnant or nursing
- Patient must agree to undergo all clinical study required follow up visits, angiograms, and imaging testing
- Patient must agree not to participate in any other clinical research study for a period of one year following the index procedure Angiographic inclusion criteria- Target Lesion/Vessel
- Target lesion(s) must be located in a native coronary artery with a vessel diameter of ≥ 2.5 and ≤3.5 mm assessed visually or by online QCA
- Target lesion(s) must measure ≤ 24 mm in length
- Target lesion(s) must be in a major artery or branch with a visually estimated stenosis of ≥ 50% and < 90% with a TIMI flow of ≥ 2. When two target lesions are treated, they must be located in separate major epicardial vessels
- The lesion(s) must be successfully pre-dilated (less than 35% DS) prior to enrollment
- The target lesion length is 24 mm and able to be covered by a single DynamX Sirolimus Bioadaptor with 2 mm of healthy vessel on either side of planned implantation site
- Treatment of a single, non-target lesion located in a separate major epicardial vessel
Exclusion Criteria:
- Patient has a diagnosis of ST elevation myocardial infarction (STEMI) within 72 hours preceding the index procedure, and CK and CK-MB have not returned within normal limits at the time of procedure
- Patient requires the use of rotational atherectomy during the index procedure
- Patient has current unstable ventricular arrhythmias
- Patient has a known left ventricular ejection fraction (LVEF) < 30%
- Patient has received a heart transplant or any other organ transplant or is on a waiting list for an organ transplant
- Patient is receiving or scheduled to receive chemotherapy for malignancy within 30 days prior to or after the procedure
- Patient is receiving immunosuppression therapy, other than steroids or has known immunosuppressive or autoimmune disease (e.g. human immunodeficiency virus, systemic lupus erythematosus etc.)
- Patient has a known hypersensitivity or contraindication to aspirin, both heparin and bivalirudin, clopidogrel, prasugrel or ticagrelor, Sirolimus, CoCr alloys, PLLA polymers or contrast sensitivity that cannot be adequately pre-medicated
- Elective surgery is planned within the first 6 months after the procedure that will require discontinuing either aspirin or clopidogrel or other P2Y12 inhibitors.
- Patient has a platelet count < 100,000 cells/mm3 or > 700,000 cells/mm3, a WBC of < 3,000 cells/mm3, or documented liver disease.
- Patient has severe renal dysfunction (CKD IV or V, eGFR <30) or is on dialysis.
- Patient has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions
- Patient has had a cerebrovascular accident (CVA) or transient ischemic neurological attack (TIA) within the past six months
- Patient has had a significant GI or urinary bleed within the past six months
- Patient has a condition that precludes safe 6 French sheath insertion; or other medical conditions or known history of substance abuse (alcohol, cocaine, heroin etc.) that may cause non-compliance with the clinical study plan, confound the data interpretation or associated with a limited life expectancy (i.e., less than one year)
- Patient is already participating in another clinical study which has not reached the primary endpoint (long-term follow-up is not an exclusion) Angiographic Exclusion Criteria Target Lesion/Vessel
1. Target/Vessel / Target lesion(s) meets any of the following criteria:
- Aorto-ostial location
- Left main location
- Located within 5 mm of the origin of the LAD or LCX
- Located within an arterial or saphenous vein graft or distal to a diseased arterial or saphenous vein graft
- Lesion involving a bifurcation with a side branch >2mm in diameter
- Previous placement of a stent within 10 mm of the target lesion
- Total or sub-total occlusion (TIMI flow ≤1)
- The proximal target vessel or target lesion is severely calcified by visual assessment, or the lesion prevents full pre-dilatation balloon expansion
- Previous intervention restenosis 2. The target vessel contains visible thrombus 3. Another clinically-significant lesion (>50%) is located in the same major epicardial vessel as the target lesion 5. Target vessel was previously treated with any type of PCI < 6 months prior to index procedure 6. Non-Target vessel was previously treated with any type of PCI < 30 days prior to the index procedure
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DynamX Sirolimus-eluting Coronary Bioadaptor System
2.5 - 3.5mm 14mm, 18mm and 28mm
|
de novo native coronary artery lesions
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Target Lesion (s) Failure
Time Frame: 6 months
|
composite endpoint of cardiac death, target vessel MI and clinically-indicated TLR
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Target Lesion (s) Failure
Time Frame: 1 month
|
composite endpoint of cardiac death, target vessel MI and clinically-indicated TLR
|
1 month
|
Target Lesion (s) Failure
Time Frame: 12 month
|
composite endpoint of cardiac death, target vessel MI and clinically-indicated TLR
|
12 month
|
cardiac death
Time Frame: 1 month
|
death from a cardiac cause
|
1 month
|
Cardiac Death
Time Frame: 6 months
|
death from a cardiac cause
|
6 months
|
Cardiac Death
Time Frame: 12 months
|
death from a cardiac cause
|
12 months
|
Non-Cardiac Death
Time Frame: 1 month
|
death from a non-cardiac cause
|
1 month
|
Non-Cardiac Death
Time Frame: 6 months
|
death from a non-cardiac cause
|
6 months
|
Non-Cardiac Death
Time Frame: 12 months
|
death from a non-cardiac cause
|
12 months
|
myocardial infarction
Time Frame: 1 month
|
all
|
1 month
|
myocardial infarction
Time Frame: 6 months
|
all
|
6 months
|
myocardial infarction
Time Frame: 12 months
|
all
|
12 months
|
myocardial infarction
Time Frame: 1 month
|
related to the target vessel
|
1 month
|
myocardial infarction
Time Frame: 6 months
|
related to the target vessel
|
6 months
|
Target Lesion Revascularization
Time Frame: 1 month
|
Clinically indicated repeat intervention within the target lesion
|
1 month
|
Target Lesion Revascularization
Time Frame: 6 months
|
Clinically indicated repeat intervention within the target lesion
|
6 months
|
Target Lesion Revascularization
Time Frame: 12 months
|
Clinically indicated repeat intervention within the target lesion
|
12 months
|
Target Vessel Revascularization
Time Frame: 1 month
|
Clinically indicated repeat intervention within the target vessel
|
1 month
|
Target Vessel Revascularization
Time Frame: 6 months
|
Clinically indicated repeat intervention within the target vessel
|
6 months
|
Target Vessel Revascularization
Time Frame: 12 months
|
Clinically indicated repeat intervention within the target vessel
|
12 months
|
Device Thrombosis
Time Frame: 1 month
|
definite and probable as classified by an Academic Research Consortium
|
1 month
|
Device Thrombosis
Time Frame: 6 months
|
definite and probable as classified by an Academic Research Consortium
|
6 months
|
Device Thrombosis
Time Frame: 12 months
|
definite and probable as classified by an Academic Research Consortium
|
12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Qualitative coronary angiography
Time Frame: 6 months
|
in-device late lumen loss
|
6 months
|
Intravascular ultrasound imaging
Time Frame: 6 months
|
Change in mean lumen area from post-procedure to 6-month follow-up
|
6 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Coronary Disease
- Coronary Artery Disease
- Physiological Effects of Drugs
- Anti-Infective Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antifungal Agents
- Sirolimus
Other Study ID Numbers
- ELX-CL-1801
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on DynamX Sirolimus-eluting Coronary Bioadaptor System
-
Elixir Medical CorporationRecruiting
-
Elixir Medical CorporationCompleted
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
National Taiwan University HospitalNot yet recruitingCoronary Artery Disease
-
Meril Life Sciences Pvt. Ltd.UnknownCoronary Artery DiseaseUnited Kingdom, Brazil, Spain, Macedonia, The Former Yugoslav Republic of, Belgium, Czechia, Latvia, Netherlands, Poland
-
Meril Life Sciences Pvt. Ltd.Not yet recruiting
-
Meril Life Sciences Pvt. Ltd.Lifecare Institute of Medical Sciences and Research Ahmedabad Gujarat IndiaCompleted
-
Sahajanand Medical Technologies Pvt. Ltd.Cardialysis BVTerminatedCoronary Artery DiseaseIndia, Brazil, Saudi Arabia
-
Samsung Medical CenterGenoss Company Limited, Suwon, KoreaRecruiting
-
Cordis CorporationConor MedsystemsTerminatedCoronary AtherosclerosisBrazil, New Zealand